In Vitro & In Vivo Diagnostic Substances Industry - SEC Form 4 Insider Trading Screener

Manufacturing Sector - Chemicals - In Vitro & In Vivo Diagnostic Substances
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
100 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
P26+1+10+15-12
S74+0-0-0+15

X

Filing Date

Trade Date

Ticker

Company

Insider Name

Insider Title

Trade Type 

Share Price

Shares Traded

Shares Owned

Own chg

Value Traded

1d ret

1w ret

1m ret

6m ret

2017-04-06
NEOGNeogen CorpBradley EdwardVPS - Sale$61.54-21,018101,512-17%-$1,293,4220-2
D
2017-04-03
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$15.43-30,000461,668-6%-$463,0050+1
2017-04-03
OXFDOxford Immunotec Global PlcSandberg Richard ADirS - Sale$15.47-3,00017,174-15%-$46,4200+1
2017-04-03
ABIOArca Biopharma, Inc.Selby Brian L.VP, FinanceS - Sale$2.46-1,1141,275-47%-$2,740+40
2017-04-04
ABIOArca Biopharma, Inc.Ozeroff Christopher DavidS.VP, GCS - Sale$2.41-41817,517-2%-$1,007+40
2017-04-04
ABIOArca Biopharma, Inc.Keuer Thomas ACOOS - Sale$2.41-39014,045-3%-$940+40
2017-04-04
ABIOArca Biopharma, Inc.Bristow Michael RPres, Chief Exec OfficS - Sale$2.41-72086,600-1%-$1,735+40
DM
2017-03-29
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$22.50-37,080284,493-12%-$834,204+10
2017-03-08
NYMXNymox Pharmaceutical CorpRobinson James GeorgeDirP - Purchase$3.59+50,0003,317,950+2%+$179,508+12+18
2017-03-24
ABIOArca Biopharma, Inc.Conway Robert EDirP - Purchase$2.59+25,00025,000New+$64,750-1-1
D
2017-03-20
OXFDOxford Immunotec Global PlcKeiley Elizabeth MSVP, GCS - Sale+OE$16.05-3,00030,614-9%-$48,150000
2017-03-17
LNTHLantheus Holdings, Inc.Avista Capital Partners Gp, LLC10%S - Sale$12.20-3,000,0003,442,208-47%-$36,600,0000+30
2017-03-17
LNTHLantheus Holdings, Inc.Venkataraman SriramDir, 10%S - Sale$12.20-3,000,0003,442,208-47%-$36,600,0000+30
2017-03-17
LNTHLantheus Holdings, Inc.Burgstahler David FDir, 10%S - Sale$12.20-3,000,0003,442,208-47%-$36,600,0000+30
2017-03-15
LNTHLantheus Holdings, Inc.Healey Timothy GSVP, CommercialS - Sale$12.42-11,31483,112-12%-$140,555-1-4-9
M
2017-03-13
ICCCImmucell Corp /de/Tomsche David ScottDirP - Purchase$5.43+2,00072,789+3%+$10,861+2+4-1
M
2017-03-09
NTLAIntellia Therapeutics, Inc.Atlas Venture Associates Ix, L.P.10%S - Sale$13.91-21,1323,729,788-1%-$293,843+1+2-3
M
2017-03-09
NTLAIntellia Therapeutics, Inc.Formela Jean FrancoisDirS - Sale$13.91-21,1323,729,788-1%-$293,843+1+2-3
2017-02-28
IDXXIdexx Laboratories Inc /deHenderson Rebecca MDirS - Sale$145.19-6,50014,950-30%-$943,7210+2+6
AD
2016-08-25
IDXXIdexx Laboratories Inc /deHenderson Rebecca MDirS - Sale+OE$110.44-9,92421,450-32%-$1,095,9530+2+6
D
2017-03-03
OXFDOxford Immunotec Global PlcEdwardson PeterChief Operations OfficerS - Sale+OE$14.92-5,92348,271-11%-$88,38200+3
2017-03-01
IDXXIdexx Laboratories Inc /deKingsley Lawrence DDirP - Purchase$146.48+1,0001,135+741%+$146,480+1+1+6
D
2017-02-27
ABIOArca Biopharma, Inc.Selby Brian L.VP, FinanceS - Sale+OE$2.56-1612,389-6%-$4120-6+2
D
2017-02-28
ABIOArca Biopharma, Inc.Ozeroff Christopher DavidS.VP, GCS - Sale+OE$2.61-46517,935-3%-$1,2140-6+2
D
2017-02-28
ABIOArca Biopharma, Inc.Keuer Thomas ACOOS - Sale+OE$2.61-46514,435-3%-$1,2140-6+2
D
2017-02-28
ABIOArca Biopharma, Inc.Bristow Michael RPres, Chief Exec OfficS - Sale+OE$2.61-76387,320-1%-$1,9910-6+2
DM
2017-02-24
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$21.39-106,920280,306-28%-$2,287,314+5+5+5
D
2017-02-22
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$142.57-35,0001,108,947-3%-$4,990,1350+3+7
M
2017-02-22
MYGNMyriad Genetics IncHenderson John TDirP - Purchase$18.66+6,00042,824+16%+$111,930+1+3+2
2017-02-16
IDXXIdexx Laboratories Inc /deEnd William TDirS - Sale$141.71-5,00050,256-9%-$708,5340+1+5
D
2017-02-17
VRMLVermillion, Inc.Feinberg Larry N* See Remarks, 10%P - Purchase$1.40+617,7319,825,289+7%+$864,823+18+21+23
D
2017-02-13
VRMLVermillion, Inc.Schuler Henri George10%P - Purchase$1.40+1,947,0528,109,840+32%+$2,725,873-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Schuler Jack W10%P - Purchase$1.40+974,0819,805,249+11%+$1,363,713-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Jordan Veronica GhDirP - Purchase$1.40+6,69570,315+11%+$9,373-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Ferrara FredCOOP - Purchase$1.40+6,6956,695New+$9,373-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Palmieri Valerie BarberPres, CEOP - Purchase$1.40+10,04258,542+21%+$14,059-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Schoen EricSVP Finance, CAOP - Purchase$1.40+3,34729,872+13%+$4,686-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Lafrance James TDirP - Purchase$1.40+6,695190,094+4%+$9,373-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Burns James SDirP - Purchase$1.40+15,000265,922+6%+$21,000+11+33+38
D
2017-02-08
IDXXIdexx Laboratories Inc /deMcKeon Brian PEVP, CFOS - Sale+OE$141.63-9,92435,311-22%-$1,405,59100+6
D
2017-02-08
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$141.63-36,2501,088,486-3%-$5,134,17100+6
D
2017-02-08
IDXXIdexx Laboratories Inc /deJunius Daniel MDirS - Sale+OE$141.75-3,0002,495-55%-$425,26400+6
D
2017-02-06
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$13.36-25,000438,495-5%-$333,875+1+1+12
2017-02-02
VIVOMeridian Bioscience IncLueke MelissaEVP, CFOP - Purchase$12.59+4,000167,071+2%+$50,356+5+5+7
2017-01-26
VIVOMeridian Bioscience IncBaldini LawrenceEVP, Pres Global OperationsP - Purchase$12.70+4,000106,934+4%+$50,800+2+1+2
D
2017-01-09
NEOGNeogen CorpParnell Jack CDirS - Sale+OE$66.04-6,00013,555-31%-$396,222-10-1
D
2017-01-09
NEOGNeogen CorpMorrical Terri AVPS - Sale+OE$66.12-27,60039,583-41%-$1,824,796-10-1
D
2017-01-04
NEOGNeogen CorpQuinlan Steven J.VP, CFOS - Sale+OE$66.13-5,35210,103-35%-$353,9470+10
2017-01-04
BIOPBioptix, Inc.Honig Barry C10%P - Purchase$4.22+4,000443,585+1%+$16,880-5-19-32
D
2016-12-23
NEOGNeogen CorpMorrical Terri AVPS - Sale+OE$65.79-21,60039,583-35%-$1,421,006-1-2-4
D
2016-12-16
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$15.07-7,052443,314-2%-$106,241-1-1-10
D
2016-12-05
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$15.00-1,140443,3140%-$17,100+5+6+6
DM
2016-12-01
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$15.00-61,808443,314-12%-$927,120-100
2016-12-02
VIVOMeridian Bioscience IncElagin Vecheslav AEVP, Research, DevelopmentS - Sale$17.30-7,88353,003-13%-$136,376+2+3+2
DM
2016-11-30
QDELQuidel Corp /de/Bujarski Robert JosephSVP, Bus Dev, GCS - Sale+OE$22.84-60,00041,896-59%-$1,370,221+1+4-4
2016-12-01
APPYBioptix, Inc.Honig Barry C10%P - Purchase$5.04+29,815500,000+6%+$150,257+1-2
2016-11-30
VIVOMeridian Bioscience IncEllingwood Dwight EDirP - Purchase$17.12+1,0207,000+17%+$17,4660+3+2
DM
2016-11-28
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$119.78-27,4241,088,431-2%-$3,284,698-3-20
DM
2016-11-28
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$22.89-72,000274,011-21%-$1,647,768-3-3-8
D
2016-11-25
QDELQuidel Corp /de/Tamerius JohnSVP, Strat, Ext AffairsS - Sale+OE$23.50-8,87823,540-27%-$208,633+1-3-8
D
2016-11-23
IDXXIdexx Laboratories Inc /deCraig ThomasDirS - Sale+OE$120.06-8,50024,283-26%-$1,020,519+1-40
2016-11-23
NEOGNeogen CorpHerbert James LCOB, CEOS - Sale$62.95-1,0001,178,2890%-$62,950-1-2+6
D
2016-11-22
NEOGNeogen CorpBradley EdwardVPS - Sale+OE$61.16-21,600122,530-15%-$1,321,0520+1+4
2016-11-21
LNTHLantheus Holdings, Inc.Burgstahler David FDir, 10%S - Sale$9.00-2,500,0004,282,208-37%-$22,500,000-1-8-13
2016-11-21
LNTHLantheus Holdings, Inc.Venkataraman SriramDir, 10%S - Sale$9.00-2,500,0004,282,208-37%-$22,500,000-1-8-13
2016-11-21
LNTHLantheus Holdings, Inc.Avista Capital Partners Gp, LLC10%S - Sale$9.00-2,500,0004,282,208-37%-$22,500,000-1-8-13
2016-11-16
VIVOMeridian Bioscience IncEberly RichardEVP; Pres, Chief Comm OfficerS - Sale$17.00-4,92648,719-9%-$83,757-10+1
D
2016-11-14
NEOGNeogen CorpHerbert James LCOB, CEOS - Sale+OE$61.00-36,000886,212-4%-$2,195,982+1+3+7
2016-11-08
OXFDOxford Immunotec Global PlcEdwardson PeterChief Operations OfficerS - Sale$14.09-4,86948,932-9%-$68,615-10+3
D
2016-11-10
NEOGNeogen CorpYeutter Clayton KDirS - Sale+OE$59.00-4,500500-90%-$265,500-2+1+6
D
2016-11-14
NEOGNeogen CorpQuinlan Steven J.VP, CFOS - Sale+OE$61.28-3,00010,103-23%-$183,842-2+1+6
D
2016-11-09
NEOGNeogen CorpQuinlan Steven J.VP, CFOS - Sale+OE$57.93-3,00010,103-23%-$173,786-1-1+8
D
2016-11-09
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$107.86-40,0001,085,855-4%-$4,314,1870+4+9
2016-11-08
IDXXIdexx Laboratories Inc /deEnd William TDirS - Sale$109.87-5,00048,654-9%-$549,3590+4+9
2016-11-08
OXFDOxford Immunotec Global PlcSandberg Richard ADirS - Sale$14.17-12,00020,174-37%-$170,007-1+1+3
M
2016-09-30
APPYVenaxis, Inc.Honig Barry C10%P - Purchase$2.52+63,42613,400-127%+$159,667-4+4+58
2016-11-07
ICCCImmucell Corp /de/Tomsche David ScottDirP - Purchase$5.19+4,00070,789+6%+$20,760+10+19
2016-11-04
VIVOMeridian Bioscience IncKraeutler John ACOB, CEOP - Purchase$16.13+5,000317,415+2%+$80,666+1+8+12
2016-11-03
VIVOMeridian Bioscience IncBaldini LawrenceEVP, Pres Global OperationsP - Purchase$16.00+4,90095,501+5%+$78,400+1+8+12
2016-10-18
ABIOArca Biopharma, Inc.Keuer Thomas ACOOS - Sale$2.45-48314,900-3%-$1,184-2-3-11-8
2016-10-05
VNRXVolitionrx LtdKratochvil David MatthewCFOP - Purchase$5.00+10,00010,000New+$50,000+4+8-20-17
DM
2016-09-30
NEOGNeogen CorpHerbert James LCOB, CEOS - Sale+OE$55.22-12,000886,212-1%-$662,582-1-1-6+13
D
2016-09-29
NEOGNeogen CorpBradley EdwardVPS - Sale+OE$53.85-5,335122,530-4%-$287,314-1-1-6+13
D
2016-09-30
NEOGNeogen CorpQuinlan Steven J.VP, CFOS - Sale+OE$55.15-3,00010,103-23%-$165,448-1-1-6+13
DM
2016-09-28
NEOGNeogen CorpMorrical Terri AVPS - Sale+OE$54.14-9,60039,583-20%-$519,7060-1-7+18
DM
2016-09-28
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$21.76-69,168274,011-20%-$1,504,768-1-1-13+3
2016-09-20
ABIOArca Biopharma, Inc.Bristow Michael RPres, Chief Exec OfficS - Sale$2.89-1,97288,083-2%-$5,699+20-13-15
2016-09-20
ABIOArca Biopharma, Inc.Keuer Thomas ACOOS - Sale$2.89-71415,383-4%-$2,063+20-13-15
2016-09-20
ABIOArca Biopharma, Inc.Ozeroff Christopher DavidS.VP, GCS - Sale$2.89-1,18518,400-6%-$3,425+20-13-15
2016-09-19
ABIOArca Biopharma, Inc.Selby Brian L.VP, FinanceS - Sale$2.91-4762,550-16%-$1,385+20-13-15
DM
2016-09-09
MYGNMyriad Genetics IncHenderson John TDirS - Sale+OE$20.49-30,00021,800-58%-$614,81600-9-8
2016-09-02
CLDXCelldex Therapeutics, Inc.Keler TiborEVP, CSOP - Purchase$3.32+3,00018,868+19%+$9,960+5+11+27+3
D
2016-08-30
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$22.00-2,832274,011-1%-$62,304-10+2+2
D
2016-08-25
IDXXIdexx Laboratories Inc /deHenderson Rebecca MDirS - Sale+OE$110.44-9,9246,754-60%-$1,095,953+2+3+1+30
2016-08-24
NEOGNeogen CorpCalk Richard E JrPres, COOS - Sale$57.47-5,4250-100%-$311,7640+10+12
D
2016-08-23
IMMUImmunomedics IncMarkison Brian ADirS - Sale+OE$2.98-15,00075,446-17%-$44,634-10+18+77
2016-08-24
IMMUImmunomedics IncStark Don CDirS - Sale$2.97-9,90055,848-15%-$29,451-10+18+77
D
2016-08-23
IMMUImmunomedics IncPaetzold Mary EDirS - Sale+OE$2.98-15,00067,474-18%-$44,673-10+18+77
D
2016-08-19
OGXIOncogenex Pharmaceuticals, Inc.Bencich JohnCFOS - Sale+OE$0.57-1,3809,484-13%-$7870-9-17+5
2016-08-22
ICCCImmucell Corp /de/Cunningham DavidDirP - Purchase$7.14+3,0009,404+47%+$21,431+1+1+10-22

AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top